T-cell receptor specific for NADH dehydrogenase subunit 5 peptide–MHC class I complex (ND5-specific TCR)

T-cell receptors (TCRs) specific for ND5 peptide–MHC class I complexes are specialized immune receptors engineered to target neoantigens derived from the NADH dehydrogenase subunit 5 (ND5) protein, which is encoded by mitochondrial DNA (mtDNA) (Lu et al., Nature, 2024). Mutations in the ND5 gene are common in various malignancies and can result in the presentation of novel, tumor-specific peptides on the cell surface via Major Histocompatibility Complex (MHC) class I molecules (Gorelick et al., Nature Reviews Cancer, 2021). These TCRs are utilized in adoptive cell therapy, specifically TCR-engineered T-cell (TCR-T) therapy, where a patient's own T cells are modified to express the ND5-specific receptor. Upon infusion, these engineered T cells circulate and bind to the specific ND5-MHC complex on tumor cells, triggering a potent cytotoxic immune response. This mechanism involves the activation of T-cell signaling pathways, leading to the secretion of perforins, granzymes, and inflammatory cytokines such as interferon-gamma, which collectively induce apoptosis in the target cancer cells. Because mtDNA mutations are often highly specific to tumor tissue, these TCRs offer a promising strategy for precision immunotherapy with a potentially favorable safety profile regarding off-target effects on healthy tissues (Smith et al., Frontiers in Immunology, 2022). Research has demonstrated that targeting these mitochondrial neoantigens can overcome some limitations of targeting nuclear neoantigens, which may be less frequent or less immunogenic in certain tumor types. Clinical development of these TCRs involves rigorous screening for HLA compatibility and mutation verification to ensure patient-specific efficacy.

Other names

ND5-targeted TCRNADH dehydrogenase subunit 5-specific T-cell receptorMitochondrial neoantigen-specific T-cell receptorND5-MHC I TCR

The TCR specifically recognizes and binds to a mutated ND5 peptide presented by MHC class I molecules on the tumor cell surface, which triggers the formation of an immunological synapse, T-cell activation, and the subsequent release of cytotoxic granules and cytokines to induce tumor cell death.